A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777
Apogee Therapeutics, Inc.
350 participants
May 14, 2025
INTERVENTIONAL
Conditions
Summary
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period. This study will be conducted in participants with atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study and who, in the opinion of the Investigator, would benefit from long-term treatment with APG777.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
APG777 subcutaneous injection
APG777 subcutaneous injection every 12 weeks
APG777 subcutaneous injection every 24 weeks
Locations(63)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07003425